Search

Background: Pulmonary embolism (PE) is one of the most fatal emergencies with a high risk of mortality. Multiple risk stratification scores have been developed to assess a patient's overall mortality risk. Objective: This study aimed to validate modified FAST and modified Bova scores for risk stratification and predicting the risk of early mortality in patients presenting with acute PE. Patients and methods: Patients admitted to Assiut University Hospital with PE were sequentially included. Pulmonary Embolism Severity Index (PESI), modified Bova, and modified FAST scores were calculated for all included patients. Results: A total of 100 patients with PE were sequentially included. It was found that predictors of in-hospital mortality in patients with PE were; chronic heart failure [odds ratio (OR)= 1.87], chronic respiratory disease (OR= 1.99), chronic kidney disease (OR= 2.01), hypotension (OR= 2.99), intermediate-high risk- PESI (simplified version; OR=2.76), intermediate-high risk modified Bova score (OR= 3.01) and intermediate-high risk modified FAST score (OR= 3.90).It was found that the modified FAST score had the best diagnostic accuracy (89.2%) with an area under the curve (AUC) 0.962, followed by the modified Bova score with accuracy 76.8% and AUC 0.761. The two scores had higher accuracy than that for PESI score (53.4%, AUC= 0.627). Conclusion: Modified FAST and modified Bova scores are simple and reliable tools for risk stratification of patients with acute PE. [ABSTRACT FROM AUTHOR]

Background Pulmonary embolism (PE) is one of the most fatal emergencies with a high risk of mortality. Multiple risk stratification scores have been developed to assess a patient’s overall mortality risk. Objective This study aimed to validate modified FAST and modified Bova scores for risk stratification and predicting the risk of early mortality in patients presenting with acute PE. Patients and methods Patients admitted to Assiut University Hospital with PE were sequentially included. Pulmonary Embolism Severity Index (PESI), modified Bova, and modified FAST scores were calculated for all included patients. Results A total of 100 patients with PE were sequentially included. It was found that predictors of in-hospital mortality in patients with PE were; chronic heart failure [odds ratio (OR)= 1.87], chronic respiratory disease (OR= 1.99), chronic kidney disease (OR= 2.01), hypotension (OR= 2.99), intermediate-high risk- PESI (simplified version; OR=2.76), intermediate-high risk modified Bova score (OR= 3.01) and intermediate-high risk modified FAST score (OR= 3.90).It was found that the modified FAST score had the best diagnostic accuracy (89.2%) with an area under the curve (AUC) 0.962, followed by the modified Bova score with accuracy 76.8% and AUC 0.761. The two scores had higher accuracy than that for PESI score (53.4%, AUC= 0.627). Conclusion Modified FAST and modified Bova scores are simple and reliable tools for risk stratification of patients with acute PE.

Objective: This study aimed to investigate the extent to which the systemic immune-inflammatory index (SII) is associated with patients with acute pulmonary embolism (PE), compare the SII with other commonly used biomarkers and scoring systems, and evaluate its suitability for routine use in PE risk classification. Materials and Methods: Patients with acute PE admitted in 2021 were retrospectively reviewed. A cut-off value for the SII was obtained to examine the predictive value of the SII for 30-day mortality as the primary outcome. The secondary outcome of the study was to compare the SII with other predictors of 30-day mortality in patients with acute PE. Results: A total of 139 patients with a mean age of 68.33±14.58 years were included in the study. The cut-off value for 30-day mortality was an SII of =0.904 (sensitivity: 88.5%; specificity: 58.4%; area under the curve: 0.803; p<0.001). Lactate, age, right ventricular dysfunction (RVD), and SII =0.904 were independent risk factors for 30-day mortality in PE (p<0.05). The SII has a strong correlation with lactate and the presence of RVD (p<0.001). Conclusion: The SII was found to be strongly associated with RVD, age, and lactate in patients with acute PE. Prospective studies may prove that the SII can fill the gap of inexpensive, rapid, and accessible prognostic biomarkers in rural emergency departments where echocardiography is not accessible. [ABSTRACT FROM AUTHOR]

Background: The Pulmonary Embolism Severity Index (PESI) is an extensively validated prognostic score, but impact analyses of the PESI on management strategies, outcomes and health care costs are lacking. Our aim was to assess whether the adoption of the PESI for patients admitted to an internal medicine ward has the potential to safely reduce the length of hospital stay (LOS). Methods: We carried out a multicenter randomized controlled trial, enrolling consecutive adult outpatients diagnosed with acute PE and admitted to an internal medicine ward. Within 48 h after diagnosis, the treating physicians were randomized, for every patient, to calculate and report the PESI in the clinical record form on top of the standard of care (experimental arm) or to continue routine clinical practice (standard of care). The ClinicalTrials.gov identifier is NCT03002467. Results: This study was prematurely stopped due to slow recruitment. A total of 118 patients were enrolled at six internal medicine units from 2016 to 2019. The treating physicians were randomized to the use of the PESI for 59 patients or to the standard of care for 59 patients. No difference in the median LOS was found between the experimental arm (8, IQR 6–12) and the standard-of-care arm (8, IQR 6–12) (p = 0.63). A pre-specified secondary analysis showed that the LOS was significantly shorter among the patients who were treated with DOACs (median of 8 days, IQR 5–11) compared to VKAs or heparin (median of 9 days, IQR 7–12) (p = 0.04). Conclusions: The formal calculation of the PESI in the patients already admitted to internal medicine units did not impact the length of hospital stay. [ABSTRACT FROM AUTHOR]

Background: Pulmonary embolism severity index and simplified pulmonary embolism severity index have been utilized in initial risk evaluation in patients with acute pulmonary embolism. However, these models do not include any imaging measure of right ventricle function. In this study, we proposed a novel index and aimed to evaluate the clinical impact. Methods: Our study population comprised retrospectively evaluated 502 patients with acute pulmonary embolism managed with different treatment modalities. Echocardiographic and computed tomographic pulmonary angiography evaluations were performed at admission to the emergency room within maximally 30 minutes. The formula of our index was as follows: (right ventricle diameter × systolic pulmonary arterial pressure-echo)/(right ventricle free-wall diameter × tricuspid annular plane systolic excursion). Results: This index value showed significant correlations to clinical and hemodynamic severity measures. Only pulmonary embolism severity index, but not our index value, independently predicted in-hospital mortality. However, an index value higher than 17.8 predicted the long-term mortality with a sensitivity of 70% and specificity of 40% (areas under the curve = 0.652, 95% CI, 0.557-0.747, P =.001). According to the adjusted variable plot, the risk of long-term mortality increased until an index level of 30 but remained unchanged thereafter. The cumulative hazard curve also showed a higher mortality with high-index value versus low-index value. Conclusions: Our index composed from measures of computed tomographic pulmonary angiography and transthoracic echocardiography may provide important insights regarding the adaptation status of right ventricle against pressure/wall stress in acute pulmonary embolism, and a higher value seems to be associated with severity of the clinical and hemodynamic status and long-term mortality but not with in-hospital mortality. However, the pulmonary embolism severity index remained as the only independent predictor for in-hospital mortality.

Background: The Pulmonary Embolism Severity Index (PESI) is an extensively validated prognostic score, but impact analyses of the PESI on management strategies, outcomes and health care costs are lacking. Our aim was to assess whether the adoption of the PESI for patients admitted to an internal medicine ward has the potential to safely reduce the length of hospital stay (LOS). Methods: We carried out a multicenter randomized controlled trial, enrolling consecutive adult outpatients diagnosed with acute PE and admitted to an internal medicine ward. Within 48 h after diagnosis, the treating physicians were randomized, for every patient, to calculate and report the PESI in the clinical record form on top of the standard of care (experimental arm) or to continue routine clinical practice (standard of care). The ClinicalTrials.gov identifier is NCT03002467. Results: This study was prematurely stopped due to slow recruitment. A total of 118 patients were enrolled at six internal medicine units from 2016 to 2019. The treating physicians were randomized to the use of the PESI for 59 patients or to the standard of care for 59 patients. No difference in the median LOS was found between the experimental arm (8, IQR 6–12) and the standard-of-care arm (8, IQR 6–12) (p = 0.63). A pre-specified secondary analysis showed that the LOS was significantly shorter among the patients who were treated with DOACs (median of 8 days, IQR 5–11) compared to VKAs or heparin (median of 9 days, IQR 7–12) (p = 0.04). Conclusions: The formal calculation of the PESI in the patients already admitted to internal medicine units did not impact the length of hospital stay.

Background: Pulmonary embolism severity index and simplified pulmonary embolism severity index have been utilized in initial risk evaluation in patients with acute pulmonary embolism. However, these models do not include any imaging measure of right ventricle function. In this study, we proposed a novel index and aimed to evaluate the clinical impact. Methods: Our study population comprised retrospectively evaluated 502 patients with acute pulmonary embolism managed with different treatment modalities. Echocardiographic and computed tomographic pulmonary angiography evaluations were performed at admission to the emergency room within maximally 30 minutes. The formula of our index was as follows: (right ventricle diameter × systolic pulmonary arterial pressure-echo)/(right ventricle free-wall diameter × tricuspid annular plane systolic excursion). Results: This index value showed significant correlations to clinical and hemodynamic severity measures. Only pulmonary embolism severity index, but not our index value, independently predicted in-hospital mortality. However, an index value higher than 17.8 predicted the long-term mortality with a sensitivity of 70% and specificity of 40% (areas under the curve = 0.652, 95% CI, 0.557-0.747, P = .001). According to the adjusted variable plot, the risk of long-term mortality increased until an index level of 30 but remained unchanged thereafter. The cumulative hazard curve also showed a higher mortality with high-index value versus low-index value. Conclusions: Our index composed from measures of computed tomographic pulmonary angiography and transthoracic echocardiography may provide important insights regarding the adaptation status of right ventricle against pressure/wall stress in acute pulmonary embolism, and a higher value seems to be associated with severity of the clinical and hemodynamic status and long-term mortality but not with in-hospital mortality. However, the pulmonary embolism severity index remained as the only independent predictor for in-hospital mortality. [ABSTRACT FROM AUTHOR]

Introduction: The predictive model for 30-day mortality of patients with acute pulmonary embolism (PE), called pulmonary embolism severity index (PESI) was designed and validated in 2005. It classifies patients into five groups based on clinical indicators, predicting 30-day mortality. It is used in daily clinical practice as a prognostic indicator and as a factor in determining the treatment approach. PESI includes only vital parameters and the most frequent comorbidities.1 We assumed that the PESI score is not specific for pulmonary embolism and that it could reflect the severity of other conditions, such as acute coronary syndrome (ACS). We aimed to evaluate the role of the PESI score in patients with ACS and to examine its effectiveness in predicting 30-day mortality. Patients and Methods: This was a retrospective, single-center, observational study conducted at Dubrava University Hospital from January 2017 to December 2023. We included all patients hospitalized for ACS within this timeframe. PESI score and follow-up data were calculated and collected using available electronic health records. The patient registry is registered at ClinicalTrials.gov (NCT06090591). Categorical variables were presented as frequencies and percentages, and continuous variables as median and interquartile range. Survival was analyzed using Kaplan-Meier estimations. Statistical analysis was performed using JASP software (v. 0.19.1). Results: We included 2312 patients with ACS; (STEMI n=1291, 55.8%; NSTEMI n=995, 43%; uAP n=26, 1.12%). Patients were divided into three risk groups according to PESI score - high risk (N=387); intermediate risk (N=454); and low risk (N=1471). Median age of participants was 64 years (IQR 56-73), and 69% were male. 30-day mortality for the low-risk group was 1.56%, for the intermediate-risk group was 4.19%, and for the high-risk group was 18.6%; overall mortality was 4.93% (Figure 1). Patients with higher PESI scores had higher mortality (p<0.001). Conclusion: PESI score is well validated in predicting mortality in patients with pulmonary embolism. In our study, it was equally good in predicting the mortality of patients with ACS. A higher PESI score accurately reflects the severity of acute conditions such as ACS, in addition to pulmonary embolism. [ABSTRACT FROM AUTHOR]

INTRODUCTION: The prognostic assessment tools such as pulmonary embolism severity ındex (PESI) and simplified PESI (sPESI) are used to predict the mortality in patients with acute pulmonary embolism. The aim of this study is to assess PESI and sPESI accuracy for the prediction of the prognostic outcomes in coronavirus disease (COVID). METHODS: This retrospective single-center was done as a cohort study. Data on hospital admission obtained from medical records were used to calculate PESI and sPESI. All the consecutive patients were assigned to low risk and high-risk groups using of PESI and sPESI. The primary outcome was hospital mortality. Accuracy of the models was assessed to predict mortality by calculating specificity, predictive values, and sensitivity of the patients at low to high risk. The area under receiver operating characteristic (ROC) was calculated to compare the discriminative power of the models. RESULTS: The PESI and sPESI had similar sensitivities (82.1% vs. 84.6%), negative predictive values (96.7% vs. 97%) for predicting mortality. The area under the ROC curve for predicting mortality was 0.82 (p

Background and Objective: The clinical profile of patients with isolated subsegmental pulmonary embolism (SSPE) remains understudied and underreported. To describe the clinical particulars of patients with SSPE, we aimed to compare clinical signs and symptoms, risk factors, lab parameters, and short-term mortality between patients with isolated SSPE and those with proximal pulmonary embolism (PE). Materials and Methods: We prospectively studied all patients with objectively confirmed PE over 4 years. Depending on the location of the most proximal pulmonary artery in which emboli were detected, patients were divided into two groups: (a) isolated SSPE and (b) proximal PE. Different clinical and laboratory parameters were compared between the two groups. Results: One hundred and fifty patients were enrolled during the 4-year study. Twenty-three (15.3%) patients were diagnosed with isolated SSPE. Compared to proximal PE, patients with SSPE are younger, are more likely to have active malignancy, less likely to have dyspnea, and more likely to have chest pain, are hemodynamically stable with a lesser prevalence of hypoxemia and hypocapnia. Patients with isolated SSPE have shorter hospital stays and lower 30-day mortality compared to proximal PE. Conclusion: Patients with isolated SSPE have a mild clinical presentation, lesser laboratory abnormalities, and a favorable short-term outcome compared to patients with proximal PE.

Purpose: To validate red cell distribution width (RDW) as an improvement in 30-day mortality risk stratification based on the Pulmonary Embolism Severity Index (PESI) in acute pulmonary embolism (PE).Patients and Methods: Prospective observational analysis of consecutive adult acute PE patients.Results: Among 731 patients, 30-day mortality was 11.9%. With adjustment for the PESI score and number of covariates, higher RDW was associated with higher mortality (RDW continuous: OR 1.21, 95% CI 1.06-1.38; Bayesian OR 1.22, 1.07-1.40; RDW 'high' [>14.5% in men >16.1% in women] vs normal: OR 3.83, 1.98-7.46; Bayesian OR 3.98, 2.04-7.68]. Crude mortality was 3.6% if PESI 86-105 (intermediate risk), but 1.2% if RDW normal and 7.1% if RDW high; 11.8% if PESI 106-125 (high risk), but 3.6% if RDW normal and 18.8% if RDW high. Adjusted probabilities showed higher mortality (ORs between 3.5-5.8) if RDW was high in any PESI risk subgroup. Crude mortality rates in two random-split subsets (n=365 and n=366) again showed the same patterns.Conclusions: On-admission RDW above the normal range improves 30-day mortality risk stratification based on PESI score in acute PE. Particularly, it corrects PESI-based intermediate-risk or high-risk allocation by reclassification into very low-risk (<3.5%) or very high-risk (>11.0%). [ABSTRACT FROM AUTHOR]

Mortality rate in COVID-19 is mainly contributed to respiratory failure caused by intractable acute respiratory distress syndrome (ARDS). However, the direct cause could be caused by diffusion failure or probably pulmonary embolism. Increased central venous pressure (CVP) will ensue in higher pulmonary vascular resistance and in turn would increase pulmonary arterial pressure. Coagulopathy is a common feature of severe acute respiratory syndrome coronavirus 2 infection, and an increase in D-dimer is the most common finding. These factors lead to thrombosis and finally embolism. We observed 14 intensive care unit-admitted COVID-19 patients suffered from CARDS from March to May 2020. We measured their CVP and D-dimer values and pulmonary embolism severity index (PESI) scores to search for possible associations. Only CVP and PESI scores were statistically significant between those three parameters (P < 0.005). Lack of regular D-dimer samples and measurements due to limited resources could be one of potential causes, which contributes to the insignificant value. Further investigations with larger samples should be advised.

Background: Accurate risk stratification is the most important step in the management of patients with acute pulmonary thromboembolism (PTE). Pulmonary embolism severity index (PESI) is a clinical tool for PTE risk stratification. CHA2DS2‐VASc score, a risk assessment tool in patients with atrial fibrillation, is recently considered for acute PTE. The presence of right ventricular (RV) dysfunction in imaging is more efficient in acute PTE risk evaluation. Hypothesis: This study aims to evaluate the association between CHA2DS2‐VASc and PESI score and each of them with RV dysfunction on computed tomography pulmonary angiography (CTPA). Methods: One hundred eighteen patients with a definite diagnosis of PTE were entered. The CHA2DS2‐VASc and PESI scores were calculated for all of them. RV dysfunction including an increase in RV to left ventricular diameter ratio, interventricular septal bowing, and reflux of contrast medium into the inferior vena cava was examined by CTPA. Results: PESI and CHA2DS2‐VASc scores were significantly associated with RV dysfunction. In addition, different classes of PESI scores were correlated with RV dysfunction. Moreover, this study showed that the CHA2DS2‐VASc score and PESI score had a positive correlation. The area under the curve value for the CHA2DS2‐VASc score was 0.625 with 61.54% sensitivity and 60.0% specificity for predicting RV dysfunction while for PESI score was 0.635 with 66.7% sensitivity and 60.0% specificity. Conclusion: This study showed that not only CHA2DS2‐VASc and PESI scores are positively correlated, but they are both associated with RV dysfunction diagnosed by CTPA. CHA2DS2‐VASc and PESI scores are able to predict RV dysfunction. [ABSTRACT FROM AUTHOR]

Copyright of Bosphorus Medical Journal / Boğaziçi Tıp Dergisi is the property of KARE Publishing and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Abstract Introduction Calcium is an important coagulation factor and hypocalcemia is related to progression and poor prognosis of many cardiopulmonary diseases. However, influence of hypocalcemia on pulmonary thromboembolism (PTE) prognosis has never been reported. This study aimed to explore its prognostic value and optimize the pulmonary embolism severity index (PESI), the widely used prognosis assessment model, based on the value. Methods PTE patients’ variables in PESI and other related clinical characteristics including admission serum calcium were collected. Associations between these variables and PTE mortality were assessed by logistic regression and cox analysis. Variables significantly associated with 30-day PTE mortality were included to develop a new prognosis prediction rule and then its validity was compared with PESI and simplified PESI (sPESI). Results 496 PTE patients were included and 49.48% patients had hypocalcemia (serum calcium ≤ 2.13 mmol/L) in admission, showing higher 7-day (P = 0.021), 14-day (P = 0.002), 30-day (13.03% vs 4.98%, P = 0.002) mortalities than patients without hypocalcemia. Adjusting for variables in PESI, hypocalcemia was further revealed to be an independent predictor of 30-day mortality (P = 0.014). The optimal prediction rule contained hypocalcemia and 5 variables in PESI and sPESI, showing higher predictive validity [sensitivity (Sen): 0.930, specificity (Spec): 0.390, area under curve (AUC): 0.800] than PESI (Sen: 0.814, Spec: 0.367, AUC: 0.716) and sPESI (Sen: 0.907, Spec: 0.216, AUC: 0.703). Conclusions Hypocalcemia is an independent predictor of the mortality following acute PTE. Based on hypocalcemia, the optimal prediction rule showed higher validity than PESI and sPESI.

Summary: Background: Pulmonary embolism (PE) is a potentially life-threatening condition that mainly affects the people of advanced age. While certain blood group phenotypes (non‑O blood group) are known risk factors for the development of venous thromboembolism (VTE), there is no research which investigated the association of blood group genotypes with severity of PE. The aim of this study was to investigate the frequency of ABO blood group genotypes among the population of patients with PE and to investigate the correlation of the pulmonary embolism severity index (PESI) score to specific ABO blood group genotypes. Material and methods: In this cross-sectional study 74 patients with PE diagnosed using CT pulmonary angiography were included and 303 blood donors without VTE or congenital thrombophilia participated as a control group. After isolation of genomic DNA ABO blood group genotype was determined using the polymerase chain reaction sequence-specific amplification (PCR-SSP) method. Results: We observed a significantly higher frequency of A1B and BB genotypes in patients with PE compared to healthy individuals (A1B 14.9% vs. 4.3%, P < 0.001; BB 5.4% vs. 0.7%, P = 0.004), while the O1O1 genotype was significantly less frequent in patients (24.3% vs. 37.3%, P = 0.036). Analyzing the severity of the clinical presentation according to the PESI score, we did not find a correlation between the severity of the clinical presentation and a certain blood type genotype. Conclusion: Patients with A1B and BB blood type genotype were at increased risk for developing pulmonary embolism, while patients with O1O1 genotype had a significantly lower risk of developing PE. [ABSTRACT FROM AUTHOR]

Objective: Acute pulmonary embolism (APE) is a serious clinical situation and atrial fibrillation (AF) is the most common arrhytmia in clinical practice. The Pulmonary Embolism Severity Index (PESI) is an accepted risk stratification tool used to predict short term mortality in APE. The aim of this study was to evaluate the relationship between the PESI score and new-onset AF in patients with APE. Methods: The records of 869 APE patients admitted between May 2012 and December 2015 were evaluated retrospectively. The PESI score was calculated for every patient. Clinical variables associated with new-onset AF in APE were assessed after the exclusion of patients with hypertension, coronary or hemodynamically significant valvular heart disease, hepatic or renal dysfunction, chronic obstructive pulmonary disease, thyroid dysfunction, diabetes mellitus, sleep apnea, any history of inflammatory or infectious disease, or recent trauma. New-onset AF was detected in 42 (4.8%) patients. Results: Age, gender, systolic and diastolic blood pressure, heart rate, fasting glucose level, serum creatinine, left ventricle ejection fraction, tricuspid annular plane systolic excursion value, and pulmonary artery systolic pressure measures were not significantly different between patients with and without AF. New-AF patients demonstrated larger LVEDD and LAD dimensions (p

Objective: Right ventricular (RV) functions are clinically important in acute pulmonary embolism (APE). Measurement of systolic function of the right ventricular outflow tract (RVOT) with echocardiography is a simple method to evaluate RV function. The aim of this study was to determine the relationship between RVOT systolic function and the Pulmonary Embolism Severity Index (PESI). Methods: A total of 151 patients diagnosed with APE by pulmonary computed tomography angiography or ventilation/perfusion scintigraphy were included. Patients were assigned to 2 groups based on the simplified PESI (sPESI): sPESI 1 patients (58.7+-12.9 years vs. 61.1+-12.7 years, respectively). Frequency of male gender was significantly higher in PESI

Background: Pan-immuno-inflammation value (PIV) is a new and comprehensive index that reflects both the immune response and systemic inflammation in the body., Objective: The aim of this study was to investigate the prognostic relevance of PIV in predicting in-hospital mortality in acute pulmonary embolism (PE) patients and to compare it with the well-known risk scoring system, PE severity index (PESI), which is commonly used for a short-term mortality prediction in such patients., Methods: In total, 373 acute PE patients diagnosed with contrast-enhanced computed tomography were included in the study. Detailed cardiac evaluation of each patient was performed and PESI and PIV were calculated., Results: In total, 60 patients died during their hospital stay. The multivariable logistic regression analysis revealed that baseline heart rate, N-terminal pro-B-type natriuretic peptide, lactate dehydrogenase, PIV, and PESI were independent risk factors for in-hospital mortality in acute PE patients. When comparing with PESI, PIV was non-inferior in terms of predicting the survival status in patients with acute PE., Conclusion: In our study, we found that the PIV was statistically significant in predicting in-hospital mortality in acute PE patients and was non-inferior to the PESI.

Background: The Pulmonary Embolism Severity Index (PESI) is a validated tool to predict 30-day all-cause mortality in patients with acute pulmonary embolism (PE) but includes only clinical variables., Aims: We aimed to determine the effectiveness of PESI extended with an echocardiographic parameter., Methods: This cross-sectional observational study included consecutive patients with acute PE diagnosed with computed tomography pulmonary angiography., Results: Of 117 subjects (57 men, 48.7%), at a median age of 69 (59-80) years, 16 patients died during the 30-day follow-up. Six modified models of PESI with an additional single echocardiographic parameter were created, which increased the predictive value of PESI (area under the curve [AUC] 0.8608): tricuspid annular plane systolic excursion (TAPSE) <18 mm, right ventricular (RV) free wall longitudinal strain (RVFWLS) >-23%, 60/60 sign, RV global longitudinal strain (RVGLS) >-16%, pulmonary ejection acceleration time (AcT) <67 ms, and thrombus in right heart cavities (AUC 0.8657 to 0.8976, respectively, all markers P <0.001). TAPSE, AcT, RVFWLS, and RVGLS showed significant correlations with the PESI score, but not a thrombus in the right heart cavity or the 60/60 sign. As PESI adjuncts, they independently predicted fatal outcomes: thrombus with hazard ratio (HR) 10.04 (95% confidence interval [CI], 2.81-37.12; P <0.001) and the 60/60 sign with HR 4.07 (95% CI, 1.27-12.81; P <0.001)., Conclusions: The quantitative echocardiographic parameters of RV systolic function and pulmonary artery blood flow are associated with the PESI score and thus increase its predictive value to a limited extent. PE- specific findings: a thrombus in the right heart cavity and the 60/60 sign are effective adjuncts to the PESI score.

Pulmonary embolism (PE) severity index (PESI) well predicts 30-day mortality in acute PE patients, yet improvements have been advocated. To evaluate predictivity of the red cell distribution width (RDW) through a comparison with PESI and to explore their interaction as a potential improvement in this respect. Retrospective analysis of consecutive adult PE patients. Of the 299 patients, 19 severely unstable died within 48 h. Among the stabilized patients, 30-day mortality was 12.1% (34/280). With PESI ≤125, mortality was 4.9% (9/185), but it was 0.7% (1/140) if RDW ≤15.0% and 17.8% (8/45) if RDW >15.0%; with PESI >125, mortality was 26.3% (25/95), but it was 15.9% (7/44) if RDW ≤15.0% and 35.3% (18/51) if RDW >15.0%. Adjusted relative risk with PESI >125 vs. ≤125 was 17.5 (95%CI 2.37–129) at RDW ≤15.0% and 1.60 (0.76–3.36) at RDW >15.0%. Thirty-day mortality predictions based on the PESI score may be improved by accounting for RDW. [ABSTRACT FROM AUTHOR]

Aim: We aimed to determine whether Neutrophil-to-Lymphocyte Ratio (NLR), Monocyte-to-Lymphocyte Ratio (MLR), Platelet-to-Lymphocyte Ratio (PLR), D-dimer, and troponin values were correlated with the simplified Pulmonary Embolism Severity Index (sPESI) in patients diagnosed as having Pulmonary Embolism (PE) in the emergency room. Material and Methods: Forty-three patients diagnosed as having PE in the emergency department were divided into low and highrisk groups according to the sPESI. We investigated whether NLR, MLR, and PLR, d-dimer, troponin-I, and Pulmonary Artery Pressure (PAP) had any effect in determining the severity of PE. Also, patients were divided into groups as those with PAP =20 or >20 mm Hg, Systolic Blood Pressure (SBP) =100 or >100 mm Hg, and those receiving or not receiving thrombolytic treatment, and compared. Results: There was a statistically significant difference between patients with low sPESI (n=10) and those with high sPESI (n=33) in terms of age (p=0.001), pulse (p=0.016), oxygen saturation (p=0.039), troponin-I (p=0.029) and PAP (p=0.032), but there was no difference between the groups in terms of NLR (p=0.796), MLR (p=0.656), PLR (p=0.863), and d-dimer (p=0.343). There was a statistically significant difference between patients who did (n=6) and did not (n=37) receive thrombolytic treatment in terms of troponin-I (p=0.012), but there was no difference between the groups in terms of NLR (p=0.861), MLR (p=0.335), and PLR (p=0.277). Conclusion: NLR, MLR, PLR and d-dimer levels were found not to be effective in determining the severity of PE. Troponin-I was associated with sPESI and was considered as an effective marker in determining the thrombolytic treatment. [ABSTRACT FROM AUTHOR]

Copyright of Archives of the Turkish Society of Cardiology / Türk Kardiyoloji Derneği Arşivi is the property of KARE Publishing and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Background: Hyponatremia has poor outcomes in other cardiopulmonary disorders, but its predictive value in predicting mortality of patients with acute pulmonary embolism is unknown. So, we evaluate the mortality of inpatients diagnosed with pulmonary embolism (PE) who had hyponatremia at the time of admission. Materials and Methods: By conducting a cohort study in patients with acute pulmonary embolism admitted in Al-Zahra Hospital during the 24 months of the date of March 2012 to March 2014. We evaluated 224 patients admitted with a primary diagnosis of PE. We used logistic regression analysis to evaluate the independent relation among serum sodium levels at the time of presentation and 30 days mortality, with severity of illness and other patient risk factors were adjusted. Results: 109 patients (48.7%) had normal sodium level (serum level >137 mmol/L). 115 patients had sodium level bellow 137 mmol/L. Of these, 56 (25%) had a sodium level 135-137 mmol/L and 59 (26.3%) had a sodium level 137, 135-137, and

Acute pulmonary embolism (PE) is a major public health problem. It is the third most common cause of death in hospitalized patients. In the United States, there are up to 600,000 cases diagnosed per year with 100,000-180,000 acute PE-related deaths. Common risk factors include underlying genetic conditions, acquired conditions, and acquired hypercoagulable states. Acute PE increases the pulmonary vascular resistance and the load on the right ventricle (RV). Increased RV loading causes compensatory RV dilation, impaired contractility, tachycardia, and sympathetic activation. RV dilation and increased intramural pressure decrease diastolic coronary blood flow, leading to RV ischemia and myocardial necrosis. Ultimately, insufficient cardiac output from the RV causes left ventricular under-filling which results in systemic hypotension and cardiovascular collapse. Current prognostic stratification strategy separates acute PE into massive, submassive, and low-risk by presence or absence of sustained hypotension, RV dysfunction, and myocardial necrosis. Massive, submassive, and low-risk acute PE have mortality rates of 25%-65%, 3%, and <1%, respectively. Current PE management includes the use of anticoagulation alone, systemic thrombolysis, catheter-directed thrombolysis, and surgical embolectomy. This article will describe the current state of practice for catheter-directed thrombolysis and its role in the management of acute PE. [ABSTRACT FROM AUTHOR]

Objective: Right ventricular (RV) functions are clinically important in acute pulmonary embolism (APE). Measurement of systolic function of the right ventricular outflow tract (RVOT) with echocardiography is a simple method to evaluate RV function. The aim of this study was to determine the relationship between RVOT systolic function and the Pulmonary Embolism Severity Index (PESI). Methods: A total of 151 patients diagnosed with APE by pulmonary computed tomography angiography or ventilation/perfusion scintigraphy were included. Patients were assigned to 2 groups based on the simplified PESI (sPESI): sPESI <1 (n=85) and sPESI Methods: A total of 151 patients diagnosed with APE by pulmonary computed tomography angiography or ventilation/perfusion scintigraphy were included. Patients were assigned to 2 groups based on the simplified PESI (sPESI): sPESI <1 (n=85) and sPESI =1 (n=66). RV conventional parameters, RVOT dimensions, and fractional shortening (RVOT-FS) were also measured.1 (n=66). RV conventional parameters, RVOT dimensions, and fractional shortening (RVOT-FS) were also measured. Results: Mean age was similar between sPESI <1 and >1 patients (58.7±12.9 years vs. 61.1±12.7 years, respectively). Frequency of male gender was significantly higher in PESI <1 group (61.2% vs. 40.2%, p=0.013). No significant differences were found between the groups in fasting glucose, serum creatinine, hemoglobin, C-reactive protein, erythrocyte sedimentation rate, troponin, and D-dimer levels, and left ventricular ejection fraction. RVOT-FS was higher in patients with sPESI <1 than in patients with sPESI ≥1 (34.41±3.56 vs. 22.98±4.22), and this difference was significant (p<0.001). Tricuspid annular plane systolic excursion values were lower and pulmonary artery systolic pressure values were higher in the sPESI ≥1 group, which was also statistically significant (p<0.05). Mortality occurred in 7 patients with sPESI <1 and in 16 patients with sPESI ≥1. The mortality rate was higher in patients with lower RVOT-FS, and a RVOT-FS <0.22 predicted mortality with a sensitivity of 54.5% (AUC: 0.674, 95% CI 0.552-0.796; p=0.009). Conclusion: The RVOT-FS is a noninvasive measurement of RV systolic function, is well-correlated with the sPESI score, and associated with mortality in patients with APE. This easily applied measurement may be used to predict short-term mortality in patients with APE. [ABSTRACT FROM AUTHOR]

Copyright of Herz is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Background: Hyponatremia has poor outcomes in other cardiopulmonary disorders, but its predictive value in predicting mortality of patients with acute pulmonary embolism is unknown. So, we evaluate the mortality of inpatients diagnosed with pulmonary embolism (PE) who had hyponatremia at the time of admission. Materials and Methods: By conducting a cohort study in patients with acute pulmonary embolism admitted in Al-Zahra Hospital during the 24 months of the date of March 2012 to March 2014. We evaluated 224 patients admitted with a primary diagnosis of PE. We used logistic regression analysis to evaluate the independent relation among serum sodium levels at the time of presentation and 30 days mortality, with severity of illness and other patient risk factors were adjusted. Results: 109 patients (48.7%) had normal sodium level (serum level >137 mmol/L). 115 patients had sodium level bellow 137 mmol/L. Of these, 56 (25%) had a sodium level 135-137 mmol/L and 59 (26.3%) had a sodium level <135 mmol/L. Patients with a serum sodium of >137,135-137, and <135 mmol/L had a cumulative 30-day mortality of 14%, 21%, and 42% (P< 0.0001), respectively. The mortality of patients with lower serum sodium was significantly increased. When the pulmonary embolism severity index and also its simplified form were replaced in the model and while some confounding variables such patients with a history of cancer, chronic pulmonary disease, heart failure, and chronic renal failure were excluded from statistics, the findings still remained similar. Conclusion: Among patients presenting with PE, hyponatremia is common and is an independent risk factor that increasing short-term mortality. This result could be encountered as a variable in determining of PE severity and mortality. [ABSTRACT FROM AUTHOR]

Although technology of diagnosis and treatment continues to improve, the mortality rate of pulmonary embolism remains high. It was detected that more than 10% of the hospital mortality is related to pulmonary embolism. Really, management of this disease is hard. It is a consensus that patients with massif pulmonary embolism, which is characterized hemodynamic impairment, and have indications of aggressive treatments such as thrombolytic. But the issue of treatment of the hemodynamically stable patients with pulmonary embolism accompanied by right ventricular dysfunction is not clear. In last year, because of the cost-effectiveness, it has been reported that lowrisk patients could treated as outpatients. Hence, it is need to make an accurate judgment of pulmonary embolism severity and prognosis. Biomarkers such as brain natriuretic peptide, N-terminal probrain natriuretic peptide, cardiac troponin, and heart-type fatty acid-binding protein are very important indicators of pulmonary embolism severity and short-term prognosis. Furthermore, it was reported that the pulmonary embolism severity index and simplified pulmonary embolism severity index are more suitable assessing the overall mortality and long-term prognosis. It is suggested that they could be used especially in identifying low risk group. In this review, in the recent literature, it will be assessed biomarkers, findings right ventricular dysfunction which were detected by imaging tool, and a few clinical prognostic model for evaluating pulmonary embolism severity and prognosis. [ABSTRACT FROM AUTHOR]

Background: Prognostic assessment is important for the management of patients with acute pulmonary embolism (APE). Pulmonary Embolism Severity Index (PESI) and simple PESI (sPESI) are new emerged prognostic assessment tools for APE. The aim of this meta-analysis is to assess the accuracy of the PESI and the sPESI to predict prognostic outcomes (all-cause and PE-related mortality, serious adverse events) in APE patients, and compare between these two PESIs. Methods: MEDLINE and EMBASE database were searched up to June 2012 using the terms "Pulmonary Embolism Severity Index" and "pulmonary embolism". Summary odds ratio (OR) with 95% confidence intervals (CIs) for prognostic outcomes in low risk PESI versus high risk PESI were calculated. Summary receiver operating characteristic curve (SROC) used to estimate overall predicting accuracies of prognostic outcomes. Results: Twenty-one studies were included in this meta-analysis. The results showed low-risk PESI was significantly associated with lower all-cause mortality (OR 0.13; 95% CI 0.12 to 0.15), PE-related mortality (OR 0.09; 95% CI 0.05 to 0.17) and serious adverse events (OR 0.34; 95% CI 0.29 to 0.41), with no homogeneity across studies. In sPESI subgroup, the OR of all-cause mortality, PE-related mortality, and serious adverse events was 0.10 (95% CI 0.08 to 0.14), 0.09 (95% CI 0.03 to 0.26) and 0.40 (95% CI 0.31 to 0.51), respectively; while in PESI subgroup, the OR was 0.14 (95% CI 0.13 to 0.16), 0.09 (95% CI 0.04 to 0.21), and 0.30 (95% CI 0.23 to 0.38), respectively. For accuracy analysis, the pooled sensitivity, the pooled specificity, and the overall weighted AUC for PESI predicting all-cause mortality was 0.909 (95% CI: 0.900 to 0.916), 0.411 (95% CI: 0.407 to 0.415), and 0.7853±0.0058, respectively; for PE-related mortality, it was 0.953 (95% CI: 0.913 to 0.978), 0.374 (95% CI: 0.360 to 0.388), and 0.8218±0.0349, respectively; for serious adverse events, it was 0.821 (95% CI: 0.795 to 0.845), 0.389 (95% CI: 0.384 to 0.394), and 0.6809±0.0208, respectively. In sPESI subgroup, the AUC for predicting all-cause mortality, PE-related mortality, and serious adverse events was 0.7920±0.0117, 0.8317±0.0547, and 0.6454±0.0197, respectively. In PESI subgroup, the AUC was 0.7856 ±0.0075, 0.8158±0.0451, and 0.6609±0.0252, respectively. Conclusions: PESI has discriminative power to predict the short-term death and adverse outcome events in patients with acute pulmonary embolism, the PESI and the sPESI have similar accuracy, while sPESI is easier to use. However, the calibration for predicting prognosis can't be calculated from this meta-analysis, some prospective studies for accessing PESI predicting calibration can be recommended. [ABSTRACT FROM AUTHOR]

Abstract: Introduction: The pulmonary embolism severity index (PESI) and the recently derived simplified PESI prognostic model have been developed to estimate the risk of 30-day mortality in patients with acute PE. We sought to assess if the PESI and simplified PESI prognostic models can accurately identify adverse events and to determine the rates of events in patients treated as outpatients. Methods: A retrospective cohort study of patients with acute pulmonary embolism (PE) presenting at the Ottawa Hospital (Canada) was conducted between 1 January 2007 and 31 December 2008. Results: Two hundred and forty three patients were included. A total of 118 (48.6%) and 81 (33.3%) were classified as low risk patients using the original and simplified PESI prognostic models respectively. None of the low risk patients died within the 3months of follow-up. One hundred and fifteen (47.3%) patients were safely treated as outpatients with no deaths or bleeding episodes and only 1 recurrent event within the first 14days or after 30days of follow-up. Thirty four (29.6%) of these outpatients were classified as high risk patients according to the original PESI and 54 (47.0%) to the simplified PESI prognostic model. Conclusion: Both PESI strategies accurately identify patients with acute PE who are at low risk and high risk for short-term adverse events. However, 30 to 47% of patients with acute PE and a high risk PESI score were safely managed as outpatients. Future research should be directed at developing tools that predict which patients would benefit from inpatient management. [Copyright &y& Elsevier]

Background: Accurate risk stratification is the most important step in the management of patients with acute pulmonary thromboembolism (PTE). Pulmonary embolism severity index (PESI) is a clinical tool for PTE risk stratification. CHA 2 DS 2 -VASc score, a risk assessment tool in patients with atrial fibrillation, is recently considered for acute PTE. The presence of right ventricular (RV) dysfunction in imaging is more efficient in acute PTE risk evaluation., Hypothesis: This study aims to evaluate the association between CHA 2 DS 2 -VASc and PESI score and each of them with RV dysfunction on computed tomography pulmonary angiography (CTPA)., Methods: One hundred eighteen patients with a definite diagnosis of PTE were entered. The CHA 2 DS 2 -VASc and PESI scores were calculated for all of them. RV dysfunction including an increase in RV to left ventricular diameter ratio, interventricular septal bowing, and reflux of contrast medium into the inferior vena cava was examined by CTPA., Results: PESI and CHA 2 DS 2 -VASc scores were significantly associated with RV dysfunction. In addition, different classes of PESI scores were correlated with RV dysfunction. Moreover, this study showed that the CHA 2 DS 2 -VASc score and PESI score had a positive correlation. The area under the curve value for the CHA 2 DS 2 -VASc score was 0.625 with 61.54% sensitivity and 60.0% specificity for predicting RV dysfunction while for PESI score was 0.635 with 66.7% sensitivity and 60.0% specificity., Conclusion: This study showed that not only CHA 2 DS 2 -VASc and PESI scores are positively correlated, but they are both associated with RV dysfunction diagnosed by CTPA. CHA 2 DS 2 -VASc and PESI scores are able to predict RV dysfunction., (© 2022 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.)

Abstract Background Prognostic assessment is important for the management of patients with acute pulmonary embolism (APE). Pulmonary Embolism Severity Index (PESI) and simple PESI (sPESI) are new emerged prognostic assessment tools for APE. The aim of this meta-analysis is to assess the accuracy of the PESI and the sPESI to predict prognostic outcomes (all-cause and PE-related mortality, serious adverse events) in APE patients, and compare between these two PESIs. Methods MEDLINE and EMBASE database were searched up to June 2012 using the terms “Pulmonary Embolism Severity Index” and “pulmonary embolism”. Summary odds ratio (OR) with 95% confidence intervals (CIs) for prognostic outcomes in low risk PESI versus high risk PESI were calculated. Summary receiver operating characteristic curve (SROC) used to estimate overall predicting accuracies of prognostic outcomes. Results Twenty-one studies were included in this meta-analysis. The results showed low-risk PESI was significantly associated with lower all-cause mortality (OR 0.13; 95% CI 0.12 to 0.15), PE-related mortality (OR 0.09; 95% CI 0.05 to 0.17) and serious adverse events (OR 0.34; 95% CI 0.29 to 0.41), with no homogeneity across studies. In sPESI subgroup, the OR of all-cause mortality, PE-related mortality, and serious adverse events was 0.10 (95% CI 0.08 to 0.14), 0.09 (95% CI 0.03 to 0.26) and 0.40 (95% CI 0.31 to 0.51), respectively; while in PESI subgroup, the OR was 0.14 (95% CI 0.13 to 0.16), 0.09 (95% CI 0.04 to 0.21), and 0.30 (95% CI 0.23 to 0.38), respectively. For accuracy analysis, the pooled sensitivity, the pooled specificity, and the overall weighted AUC for PESI predicting all-cause mortality was 0.909 (95% CI: 0.900 to 0.916), 0.411 (95% CI: 0.407 to 0.415), and 0.7853±0.0058, respectively; for PE-related mortality, it was 0.953 (95% CI: 0.913 to 0.978), 0.374 (95% CI: 0.360 to 0.388), and 0.8218±0.0349, respectively; for serious adverse events, it was 0.821 (95% CI: 0.795 to 0.845), 0.389 (95% CI: 0.384 to 0.394), and 0.6809±0.0208, respectively. In sPESI subgroup, the AUC for predicting all-cause mortality, PE-related mortality, and serious adverse events was 0.7920±0.0117, 0.8317±0.0547, and 0.6454±0.0197, respectively. In PESI subgroup, the AUC was 0.7856±0.0075, 0.8158±0.0451, and 0.6609±0.0252, respectively. Conclusions PESI has discriminative power to predict the short-term death and adverse outcome events in patients with acute pulmonary embolism, the PESI and the sPESI have similar accuracy, while sPESI is easier to use. However, the calibration for predicting prognosis can’t be calculated from this meta-analysis, some prospective studies for accessing PESI predicting calibration can be recommended.

Pulmonary thromboembolism (PTE) is an acute and rather frequent cardiovascular condition which has considerable short-term mortality and potential of causing severely impairing long-term morbidity such as chronic thromboembolic pulmonary hypertension. After the diagnosis of PTE is confirmed risk stratification for early mortality should be undertaken. According to the latest ESC Guidelines on the diagnosis and management of acute pulmonary embolism therapeutic decision making varies depending on a risk category the affected patient belongs to. Variables taken in account when assessing early mortality risk include shock or hypotension, PESI (Pulmonary Embolism Severity Index), imaging (echocardiography, CT) signs of right ventricular dysfunction and positivity of cardiac laboratory biomarkers. We distinguish low, intermediate (divides in intermediate-low and intermediate-high subgroup) and high risk group. Therapeutic choice for patients in high risk group is primary reperfusion which was mostly confined to administration of systemic thrombolytic treatment, usually with the use of recombinant tissue plasminogen activator. However, a significant number of patients have well-established contraindications for systemic thrombolytic treatment. Catheter-directed thrombectomy is an invasive percutaneous, transvenous procedure which combines direct or ultrasound assisted pulmonary thrombus destruction and aspiration with possibility of local administration of thrombolytic agent. Even though there are various techniques, most of recently published authors gained clinical experience from successful applications of the AngioJet,m (Boston Scientific, MA, USA) pharmacomechanical thrombectomy device. It consists out of console and rheolytic thrombectomy catheter. It is a 6 Fr, 120 cm long, over the wire, dual lumen catheter. The console generates power which forces saline solution through the series of high pressure jets located on the tip of the catheter what disrupts the thrombus which is then aspirated into the low-pressure second lumen. There is an option of targeted administering of thrombolytic agent. Commonly encountered complications include bradycardia and hemoglobinuria. Rare, but potentially fatal complications include perforation of pulmonary artery, pericardial tamponade and life-threatening hemoptysis. Method was first described by Koning et al in 1997 and since then only small patient series were reported with the largest one including 50 patients. Despite that, cumulative data on roughly 600 patients suggest safety of the method with survival rates of nearly 90%.*'3 Conclusion: Catheter directed thrombectomy should be considered as a treatment of choice in high risk pulmonary thromboembolism patients with contraindication for systemic thrombolytic treatment. However, optimal use of the described method urges more prospective data. [ABSTRACT FROM AUTHOR]

Acute pulmonary embolism (PE) still represents a challenge regarding a rapid diagnosis and a risk-adapted therapy. In the 2014 guidelines of the European Society of Cardiology (ESC) on the diagnosis and management of acute PE, several new recommendations have been issued based on new study data. Some established scores for risk stratification were developed further and there is now good evidence for the use of age-adjusted D-dimer cut-off levels. For the risk stratification in patients without clinical features of shock, the utilization of the pulmonary embolism severity index (PESI) and simplified PESI (sPESI) scores is recommended. In patients with intermediate risk, right ventricular morphology and function can be evaluated by computer tomography or echocardiography and biomarkers facilitate further risk stratification. For the treatment of patients with venous thromboembolism with or without PE, the non-vitamin K-dependent oral anticoagulants (NOACs) are a safe alternative to the standard anticoagulation regimen with heparin and vitamin K antagonists. Systemic thrombolytic therapy should be restricted to patients with high risk or intermediate high risk with hemodynamic instability. Finally, new recommendations for the diagnosis and therapy of patients with chronic thromboembolic pulmonary hypertension (CTEPH), with cancer or during pregnancy are given.

Pulmonary embolism (PE) remains a major healthcare problem. PE presents with a variety of non-specific symptoms, and confirmation of diagnosis involves the use of clinical risk scores, scanning techniques and laboratory tests. Treatment choice is informed by the risk of sudden death, with high-risk patients recommended to receive thrombolytic therapy or thrombectomy. Patients with less severe presentations are given anticoagulant therapy, traditionally with parenteral heparins in the acute phase of treatment, transitioning to oral vitamin K antagonists (VKAs). The limitations of these agents and the introduction of non-VKA oral anticoagulants challenge this paradigm. To date, clinical studies of four non-VKA oral anticoagulants to treat acute thrombosis have been published, and rivaroxaban is now approved for treatment and prevention of PE (and deep vein thrombosis). Rivaroxaban and apixaban alone, and dabigatran and edoxaban after parenteral anticoagulant induction, were non-inferior to enoxaparin/VKA for the prevention of recurrent venous thromboembolism; the risk of major bleeding was similar with dabigatran and edoxaban and significantly reduced with rivaroxaban and apixaban. Patients with an initial PE are recommended to receive continued anticoagulation for 3 months or longer, depending on individual risk factors, and studies of non-VKA oral anticoagulants have shown a continued benefit for up to 2 years, without a significantly increased risk of major bleeding. Given that the non-VKA oral anticoagulants are given at fixed doses without the need for routine coagulation monitoring, their adoption is likely to ease the burden on both PE patients and healthcare practitioners when longer-term or extended anticoagulation is warranted., (© 2013.)

Background: Patients with acute deep vein thrombus (DVT) can safely be treated as outpatients. However the role of outpatient treatment in patients diagnosed with a pulmonary embolism (PE) is controversial. We sought to determine the safety of outpatient management of patients with acute symptomatic PE., Materials and Methods: A systematic literature search strategy was conducted using MEDLINE, EMBASE, the Cochrane Register of Controlled Trials and all EBM Reviews. Pooled proportions for the different outcomes were calculated., Results: A total of 1258 patients were included in the systematic review. The rate of recurrent venous thromboembolism (VTE) in patients with PE managed as outpatients was 1.47% (95% CI: 0.47 to 3.0%; I(2): 65.4%) during the 3 month follow-up period. The rate of fatal PE was 0.47% (95% CI: 0.16 to 1.0%; I(2): 0%). The rates of major bleeding and fatal intracranial hemorrhage were 0.81% (95% CI: 0.37 to 1.42%; I(2): 0%) and 0.29% (95% CI: 0.06 to 0.68%; I(2): 0%), respectively. The overall 3 month mortality rate was 1.58% (95% CI: 0.71 to 2.80%; I(2): 45%). The event rates were similar if employing risk stratification models versus using clinical gestalt to select appropriate patients for outpatient management., Conclusions: Independent of the risk stratification methods used, the rate of adverse events associated with outpatient PE treatment seems low. Based on our systematic review and pooled meta-analysis, low-risk patients with acute PE can safely be treated as outpatients if home circumstances are adequate., (© 2013.)

Background: Assessment of pre-test probability of pulmonary embolism (PE) and prognostic stratification are two widely recommended steps in the management of patients with suspected PE. Some items of the Geneva prediction rule may have a prognostic value. We analyzed whether the initial probability assessed by the Geneva rule was associated with the outcome of patients with PE., Methods: In a post-hoc analysis of a multicenter trial including 1,693 patients with suspected PE, the all-cause death or readmission rates during the 3-month follow-up of patients with confirmed PE were analyzed. PE probability group was prospectively assessed by the revised Geneva score (RGS). Similar analyses were made with the a posteriori-calculated simplified Geneva score (SGS)., Results: PE was confirmed in 357 patients and 21 (5.9%) died during the 3-month follow-up. The mortality rate differed significantly with the initial RGS group, as with the SGS group. For the RGS, the mortality increased from 0% (95% Confidence Interval: [0-5.4%]) in the low-probability group to 14.3% (95% CI: [6.3-28.2%]) in the high-probability group, and for the SGS, from 0% (95% CI: [0-5.4%] to 17.9% (95% CI: [7.4-36%]). Readmission occurred in 58 out of the 352 patients with complete information on readmission (16.5%). No significant change of readmission rate was found among the RGS or SGS groups., Conclusions: Returning to the initial PE probability evaluation may help clinicians predict 3-month mortality in patients with confirmed PE. (ClinicalTrials.gov: NCT00117169)., (Copyright © 2013 Elsevier Ltd. All rights reserved.)